Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 13/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.55 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.55 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.55 |
| ▸ | SLCO2A1 | Q92959 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3992485 | 1.00 | PTGFR (0.55) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4111896 | 0.85 | PTGER4 (0.57) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4112689 | 0.85 | ALDH1A1 (0.57) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4111899 | 0.85 | PTGER4 (0.57) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4112690 | 0.85 | ALDH1A1 (0.57) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4192876 | 0.85 | ALDH1A1 (0.46) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4192872 | 0.85 | ALDH1A1 (0.46) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL11095586 | 0.83 | PTGFR (0.67) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4100854 | 0.79 | MAPT (0.41) | PTGFRTBXA2RPTGER3LMNAALDH1A1 | |
| SCHEMBL4100856 | 0.79 | MAPT (0.41) | PTGFRTBXA2RPTGER3LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009065081-A2 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090124695-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124695-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | PTGER1, PTGER4, PTGER2 | PTGFR 10/4885TBXA2R 18/4885PTGER3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.